Skip to main
TRAW

Traws Pharma (TRAW) Stock Forecast & Price Target

Traws Pharma (TRAW) Analyst Ratings

Based on 1 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Traws Pharma is currently seen as a neutral stock, with a reduced conviction due to recent setbacks in its clinical trials by regulatory agencies. The company has reduced visibility on its next value driver, with its influenza program being pushed back due to regulatory concerns. Despite this, the company's focus on its COVID program, along with cost cuts and a strong pipeline of products, may still provide opportunities for growth in the future.

Bears say

Traws Pharma is currently facing significant risks, including financing, clinical trial, regulatory, delisting, and bankruptcy risks. These risks could potentially hinder the company's ability to successfully develop and commercialize its product candidates and generate revenue. While the company has announced the initiation of a hantavirus/Ebola antiviral program, the early development status and uncertainty around the program's potential commercial success limits its current value. Additionally, Traws Pharma's success in the competitive antiviral market will depend on its ability to differentiate its products and secure a sustainable market for COVID, hantavirus, and Ebola.

Traws Pharma (TRAW) has been analyzed by 1 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Traws Pharma (TRAW) Forecast

Analysts have given Traws Pharma (TRAW) a Hold based on their latest research and market trends.

According to 1 analysts, Traws Pharma (TRAW) has a Hold consensus rating as of Jun 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Traws Pharma (TRAW)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.